Envisagenics picks up $2.25 mln seed
Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
28 November 2017•1 min read
Envisagenics, which is focused on discovering RNA therapeutics, has raised $2.25 million in seed funding. Dynamk Capital led the round.
